(R)-N-(1-(4-(6-bromohexyloxy)phenyl)propan-2-yl)-N-methylprop-2-yn-1-amine | 1430326-10-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-N-(1-(4-(6-bromohexyloxy)phenyl)propan-2-yl)-N-methylprop-2-yn-1-amine
• 英文别名: (2R)-1-[4-(6-bromohexoxy)phenyl]-N-methyl-N-prop-2-ynylpropan-2-amine
• CAS: 1430326-10-5
• 化学式: C₁₉H₂₈BrNO
• 分子量: 366.341
• InChiKey: SAUPUPDCDOPVEM-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-胺-1,2,3,4-四氢盐酸氯酯 、 (R)-N-(1-(4-(6-bromohexyloxy)phenyl)propan-2-yl)-N-methylprop-2-yn-1-amine 在 potassium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 反应 24.33h， 以42.7%的产率得到(R)-N-(6-(4-(2-(methyl(prop-2-ynyl)amino)propyl)phenoxy)hexyl)-1,2,3,4-tetrahydroacridin-9-amine
  参考文献：
  名称：

  A novel series of tacrine–selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease

  摘要：

  A novel series of tacrine-selegiline hybrids was synthesised and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B). The results demonstrate that most of the synthesised compounds exhibit high inhibitory activity. Among these compounds, compound 8g provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 mu M, and 0.1810 mu M for AChE, BuChE, MAO-A and MAO-B, respectively). These results indicated that 8g has the potential to be a multi-functional candidate for Alzheimer's disease. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.039
• 作为产物：
  描述：

  对甲氧基苯基丙酮 在 甲酸 、 L-酒石酸 、 palladium 10% on activated carbon 、 platinum on activated charcoal 、 氢气 、 三溴化硼 、 potassium carbonate 、 potassium iodide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 68.0h， 生成 (R)-N-(1-(4-(6-bromohexyloxy)phenyl)propan-2-yl)-N-methylprop-2-yn-1-amine
  参考文献：
  名称：

  A novel series of tacrine–selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease

  摘要：

  A novel series of tacrine-selegiline hybrids was synthesised and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B). The results demonstrate that most of the synthesised compounds exhibit high inhibitory activity. Among these compounds, compound 8g provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 mu M, and 0.1810 mu M for AChE, BuChE, MAO-A and MAO-B, respectively). These results indicated that 8g has the potential to be a multi-functional candidate for Alzheimer's disease. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.039

文献信息

• A novel series of tacrine–selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease
  作者：Chuanjun Lu、Qi Zhou、Jun Yan、Zhiyun Du、Ling Huang、Xingshu Li

  DOI：10.1016/j.ejmech.2013.01.039

  日期：2013.4

  A novel series of tacrine-selegiline hybrids was synthesised and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B). The results demonstrate that most of the synthesised compounds exhibit high inhibitory activity. Among these compounds, compound 8g provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 mu M, and 0.1810 mu M for AChE, BuChE, MAO-A and MAO-B, respectively). These results indicated that 8g has the potential to be a multi-functional candidate for Alzheimer's disease. (C) 2013 Elsevier Masson SAS. All rights reserved.